Oncogenic Drivers in Lung Cancer
From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.
From the 2014 ASCO Annual Meeting, internationally renowned lung cancer expert David P. Carbone, MD, PhD, discusses his recent study, “Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma,” published in the Journal of Clinical Investigation, in which he and coauthors suggest an alternate approach to discovering driver mutations.
With this year being the 50th anniversary of ASCO's first annual meeting, Dr. Carbone also tells us about the early involvement with ASCO of his father, the eminent oncologist Paul Peter Carbone, and highlights some of his father's research in hematology.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
